17,261 trials
Myeloma
Primary: Time From Transplant to Neutrophil Count Recovery — 12; 12 days — p=0.89
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Graft-versus-host Disease
Primary: Percentage of Participants With Grade II-IV Acute GvHD by Day +120 — 17.4 Percentage of participants
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 6; 2; 2; 0 Participants
Lymphoid Leukemia · Myeloid Leukemia · Monocytic Leukemia
Primary: The Proportion of Patients That Experience Non-relapse Mortality (NRM) — 5 Participants
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Liposarcoma · Osteogenic Sarcoma · Ewing/Ewing-like Sarcoma
Primary: Progression-free Survival (PFS). Cohort A and Cohort B — 1.87; 2.07; 3.6; 1.7 months
Multiple Myeloma
Primary: Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy — 6; 4 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Erythroid Leukemia · Acute Megakaryoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLT) — 2; 1; 0; 0 Participants
Pulmonary Artery Hypertension
Primary: Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) — 21.2; -74.9 dyne•s/cm^5 — p=0.0310
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Chronic Hepatitis B
Primary: Mean Change in Quantitative Hepatitis B Surface Antigen (qHBsAg) — 0.0; 0.0; 0.0; 0.0 log10 IU/mL — p=1.000